Ulipristal

BreastfeedingGeriatricPediatric
  • TRADE NAMES: ella (Watson); ellaOne (HRA Pharma)
  • INDICATIONS: Emergency contraception within 120 hours (5 days) of unprotected sexual intercourse or contraceptive failure
  • CLASS: Progestogen antagonist
  • HALF-LIFE: 32 hours
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Antacids, Barbiturates, Bosentan, Carbamazepine, Clarithromycin, Conivaptan, CYP3A4 inducers, Dabigatran, Deferasirox, Digoxin, Efavirenz, Felbamate, Griseofulvin, H2-receptor antagonists, Hypericum perforatum, Itraconazole, Ketoconazole, Levonorgestrel, Nefazodone, Omeprazole, Oxcarbazepine, Pantoprazole, Phenobarbital, Phenytoin, Progestogens, Proton pump inhibitors, Rifampin, Rifapentine, Ritonavir, St John's Wort, Telithromycin, Topiramate

PREGNANCY CATEGORY: X

Our database has 57 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN
MUCOSAL
CARDIOVASCULAR
CENTRAL NERVOUS SYSTEM
NEUROMUSCULAR/SKELETAL
GASTROINTESTINAL/HEPATIC
RESPIRATORY
ENDOCRINE/METABOLIC
GENITOURINARY
RENAL
OCULAR
OTHER


Visit Informa

Click on the DRUG REVIEW ARTICLE tab (above) to see a review of ulipristal in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)

Page last updated 09/19/2018

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric